Description: FK506 is 23-membered macrolide lactone discovered in 1984, by Kino T, Hatanaka H and Hashimoto M. [reference 2] FK506 exhibits potent inhibitory effect on T- lymphocyte activation. It binds to immunophilins FK506 binding proteins (FKBP-12) and a complex of FKBP-12, calcium, calmodulin and calcineurin is formed, inhibiting phosphatase activity of calcineurin. This prevents dephosphorylation and translocation of nuclear factor of activated T – cells (NF-AT) and inhibits transcription of early T-cell activation gene, Interleukin-2, Tumour Necrosis Factor (TNF-a) and proto-oncogenes; suppressing expression of IL-2 and IL-7 receptor. This results in inhibition of T-lymphocyte activation. FK506 also inhibits the mixed lymphocyte reaction, generation of cytotoxic T-cells and T-cell dependent B-cell activation.
Solubility ( literature ): FK506 is soluble in Methanol, Ethanol, Acetone, Ethyl Acetate, Diethyl ether, Chloroform, Dicloromethane. FK506 is sparingly soluble in Hexane, Petroleum ether. FK506 is insoluble in water
Applications: FK506 (Tacrolimus) is used as an immunosuppressant at organ transplantations. For experimental uses of FK506 (Tacrolimus) read also United States Patent Application 20090098200
Composition: Ingredient type Fermentek product
Disclaimer: For Research use only, Not for Human or Drug use, Not extracted from humans or animals, Refer to MSDS for further safety and handling instructions
Names and identifiers: Synonyms: FK506, Tacrolimus, RTECS: KD4200000
Pub 1:
Source: Streptomyces sp.
Chemical name: FK506
InChl Key: QJJXYPPXXYFBGM-LFZNUXCKSA-N